Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an <i>In Vivo</i> Guinea Pig Cutaneous Infection Model

Abstract

<i>Candida auris</i> has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, animals were evaluated for clinical appearance, tissue fungal burden, histology, and pharmacokinetics. Oral dosing with 10 mg/kg ibrexafungerp (IBX) reduced the severity of lesions and significantly reduced the <i>C. auris</i> fungal burden in infected animals compared with untreated controls. This indicates promise for use of IBX in controlling skin infection and colonization of hospitalized patients.